Previous 10 | Next 10 |
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
PRINCETON, N.J. , Jan. 8, 2020 /PRNewswire/ -- Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that Thomas McLaughlin has been appointed Vice President, North America . In this role, McLaughlin will oversee and ensure the growth of Gue...
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020, at 4:00 p.m. Pacific Time. The presentation and Q&a...
In the world of biotech and pharma, the JP Morgan Healthcare Conference serves as an unofficial annual kick-off event. Industry leaders, investors, analysts, and investment bankers overrun Union Square in San Francisco as they attempt to garner a few precious minutes of face-to-face time ...
Welcome to a special New Year's Day edition of Seeking Alpha's Stocks to Watch series - a preview of some key events and catalysts to look for in the new year. A podcast of Stocks to Watch is available every Sunday on Seeking Alpha , Apple Podcasts , Stitcher and Spotify (click the highl...
Q4 2019 has been the best quarter ([[IBB]] up 22.5% [[XBI]] up 26.7%) for biotech investors since Q1 2015, which was the top of 2014-2015 rally. This 20+% rally is largely attributed to Fed's overall easing stance, increased mergers & acquisitions, positive regulatory backdrop, solid trial...
There's never been a good time to have a rare blood-based disorder, but there's also never been a better time than right now. That's because the U.S. Food and Drug Administration (FDA) has been unusually quick to review and approve new drug applications for treatments with life-saving poten...
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Neutral rating and $33 (4% upside) price target at H.C. Wainwright. More news on: Aimmune Therapeutics, Inc., Ampio Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Syros Pharmaceuticals (NASDAQ: SYRS ) ( +6% premarket) and Global Blood Therapeutics (NASDAQ: GBT ) ( -6% premarket) will collaborate to discover, develop and commercialize new treatments for sickle cell disease and beta thalassemia. More news on: Syros Pharmaceuticals, Inc.,...
Aduro BioTech (NASDAQ: ADRO ) -10% after Novartis bails on Aduro's ADU-S100 . More news on: Aduro BioTech, Inc., ADDvantage Technologies Group, Inc., FedEx Corporation, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...